Cargando…
New onset severe ulcerative colitis following Ixekizumab therapy
Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
UMF “Gr. T. Popa” Iasi Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/ https://www.ncbi.nlm.nih.gov/pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 |